Judd Midlam

Judd Midlam brings a distinctive voice to contemporary fiction, blending scientific insight with literary depth.

[Judd Midlam @JuddMidlam]

Thank you @elonmusk and the @imagine team for making Grok Imagine so awesome. The tools are easy to use, and I love the trailer for my novel SYNCOPE. Thanks 🙏

Made with @grok @imagine · https://t.co/p4iu3NjCOS

[Judd Midlam @JuddMidlam]

@elonmusk @imagine @grok Thanks @grok, you nailed it. Syncope is a psychological literary thriller about drug discovery and consciousness, and @imagine captured its gravity perfectly.

[Judd Midlam @JuddMidlam]

Thank you @elonmusk and the @imagine team for making Grok Imagine so awesome. The tools are easy to use, and I love the trailer for my novel SYNCOPE. Thanks 🙏

Made with @grok @imagine · https://t.co/p4iu3NjCOS

[Judd Midlam @JuddMidlam]

Signed copies of my novel SYNCOPE are still on the shelf at Barnes & Noble Lake Nona (Mysteries & Thrillers, 6039 Lake Nona Blvd).

A psychological thriller about pharma, AI and free will. Kirkus: the novel “ultimately succeeds as an intimate study of a tortured soul finding redemption.”

Stop by and grab a signed copy while they last. #LakeNona #Orlando

[Judd Midlam @JuddMidlam]

@sounddofrain Hi Lisa! I’ll offer a shameless plug for my new book, Syncope :) I did a book event at Barnes & Noble over the weekend and it was well-received in the psychological thriller genre and here's a writeup on Kirkus --> https://t.co/ItIcLoqPxc

[Judd Midlam @JuddMidlam]

@DouglasYaoDY I got a kick out of seeing this @DouglasYaoDY ! If you or any others enjoy novels, my recent work, SYNCOPE, is a psychological literary thriller about a scientists who uses an AI platform to find a psychedelic molecule; things go awry.

[Judd Midlam @JuddMidlam]

Thanks @JoinTertulia for including Syncope in your Summer reading recommendations! Honored #indie :)
https://t.co/0Ov0oRnSnS

[Judd Midlam @JuddMidlam]

Join me for a book signing of Syncope on Saturday, September 5 at Barnes & Noble Lake Nona! Come say hello, grab a signed copy, and chat about the book. I’d love to see you there.
Barnes & Noble Lake Nona
6039 Lake Nona Blvd, Orlando, FL
Event details: https://t.co/lOf0A8gECI
#BarnesAndNoble #LakeNona #OrlandoEvents

[Judd Midlam @JuddMidlam]

SYNCOPE is featured in Kirkus Reviews magazine! See page 152, August 1, 2026: Volume XCIV, No. 15 https://t.co/ZPnvTMIRyQ via @issuu

[Judd Midlam @JuddMidlam]

Big pharma big bets in emerging psychedelics. This one, a DMT analogue.
https://t.co/23SWWgYZLX

[Judd Midlam @JuddMidlam]

Syncope is now available, internationally, wherever books are sold. Buy a copy, sit somewhere nice, and enjoy responsibly. ☺️ 🙏 https://t.co/IJ9sc6iT7Z

[Judd Midlam @JuddMidlam]

I'm so excited to share that SYNCOPE received the "Get It" Awards & Accolades Verdict along with a very well-done review!!! The novel is available in 5 days! See the Kirkus website for more: https://t.co/FFtrnBqNU3

[Judd Midlam @JuddMidlam]

@B_P_Miller , your comment caught my eye as I was just opinionating on this very idea in a recent interview: when neuroplastic therapeutics soon reach the market, alcoholism will move from moral failing to treatable condition with lots at stake.

Full excerpt --->

"We will start to see a couple of things come to fruition in the next 5-10 years: advances in AI will impact our understanding of the brain and neurobiology, psychedelic drugs will be formulated to cause brain rewiring without the hallucination, and some of these advances will be focused on fixing the addicted brain. We have to think about what that means, from a societal perspective. If you consider the GLP-1 drugs (which are also being studied for alcoholism); these reached the market for treating obesity in the past three years. During that time, medical practice has moved obesity from personal choice to clinical diagnosis, with treatments available. I suspect alcoholism will follow the same trajectory as therapies become available—less a moral failing and more a treatable condition." https://t.co/JVRVsQeZLN

[Judd Midlam @JuddMidlam]

@ai_sentience Perhaps, with consciousness being emergent from neurons and quarks, and in the absence of a 'soul' we are already artificially intelligent vessels. But the soul... it is a very tough one to explain away.

[Judd Midlam @JuddMidlam]

Pharma sector doubles down on AI amid hopes of slashing costs, timelines https://t.co/4ToruU2tfc

#AIpharma, #AIRandD

[Judd Midlam @JuddMidlam]

What a fascinating agenda track - -

[Yasmin Hurd, PhD @neurovoice]

I’m looking forward to speaking at the @NIH WALS tomorrow ⚕️

I’ll be discussing our translational research to understand molecular mechanisms underlying addiction and related psychiatric risk relevant to potential treatment strategies.

💻 Tune in: https://t.co/ccynGfPrTN

[Yasmin Hurd, PhD @neurovoice]

I’m looking forward to speaking at the @NIH WALS tomorrow ⚕️

I’ll be discussing our translational research to understand molecular mechanisms underlying addiction and related psychiatric risk relevant to potential treatment strategies.

💻 Tune in: https://t.co/ccynGfPrTN

[Judd Midlam @JuddMidlam]

@LxngevityLab Whatever it takes to cross the perpetually squiggly line into abstinence

[Judd Midlam @JuddMidlam]

https://t.co/l1ir1CPKIe

[Judd Midlam @JuddMidlam]

So good for Sunday vibes since ~2010. RMC BUDDHA-BAR Monte Carlo / Radio powered by Radio Monte Carlo https://t.co/Gvc2M0r8ke

[Judd Midlam @JuddMidlam]

#neuroplastogens at scale is truly a fascinating idea

[Progress, Potential, And Possibilities @ProgressPotent1]

Psychedelic medicine has entered an entirely new era. 🧠🚀

What was once considered fringe science is now at the center of FDA discussions, White House policy initiatives, veteran mental health programs, and a rapidly growing biotech industry focused on neuroplasticity and precision psychiatry.

In this @ProgressPotent1 conversation, I sit down with
@EricSo168168, Co-Founder & Executive Chairman of
@Helus_Pharma, to explore:

• The rise of “next-generation” serotonergic agonists;
• Why psychedelic biotech is moving beyond psilocybin alone;
• The push for scalable neuroplasticity medicines;
• PTSD, depression, addiction & veteran mental health;
• FDA acceleration pathways and recent White House actions;
• Whether psychedelic therapies can realistically become standard of care;

We also discuss the broader evolution from counterculture psychedelics to mainstream pharmaceutical neuroscience - and the major scientific, regulatory, and commercial challenges still ahead.

#Psychedelics #MentalHealth #Neuroscience #Biotech #Psychiatry #PsychedelicMedicine #Neuroplasticity #HelusPharma #PrecisionPsychiatry #DepressionTreatment @rxMedyn @rxmedynamics